Thomas W. Beetham - 03 Mar 2026 Form 4/A - Amendment Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Chief Operating Officer
Issuer ticker: VRDN
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 09 Mar 2026, 19:42:53 UTC
Original report date: 04 Mar 2026
Prior SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/Jennifer Tousignant, Attorney-in-fact

Key filing fact

Thomas W. Beetham filed Form 4/A - Amendment for Viridian Therapeutics, Inc.\DE (VRDN) on 09 Mar 2026.

Key facts

This page summarizes Thomas W. Beetham's Form 4/A - Amendment filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Mar 2026, 19:42.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001741382 Primary reporting owner

Beetham Thomas W.

Relationship: Chief Operating Officer
Address: C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM
Signature: /s/Jennifer Tousignant, Attorney-in-fact
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRDN transaction

Common Stock

Tax liability

Transaction value
Shares: -3,048
Change %: -19%
Price: $30.19^*
Shares after: 13,361
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.